On Monday shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) closed at $18.00. On Apr 29, Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced that the U.S. Department of Defense (“DoD”) awarded the company a grant1 worth approximately $2 million to conduct a Phase 2 clinical trial investigating FX006 as treatment for osteoarthritis (“OA”) pain in active military and medically retired veterans with post-traumatic OA of the knee. FX006 is a steroid, triamcinolone acetonide or TCA, formulated for sustained-release, delivered by intra-articular (“IA” or “in the joint”) injection for patients with OA pain of the knee. Flexion announced in February that dosing had begun in a Phase 3 clinical trial of FX006 as a treatment for pain associated with OA of the knee.
United States Steel Corp. (NYSE:X) in last trading activity increased 2.06% to close at $23.74. Company weekly performance is -9.60% while its quarterly performance stands at -1.65%. United States Steel Corp. (NYSE:X) is -48.82% away from its 52 week high. United States Steel Corporation (NYSE:X) announced that its Board of Directors declared a dividend of five cents per share on U. S. Steel Common Stock. The dividend is payable June 10, 2015, to stockholders of record at the close of business May 13, 2015.
On last trading day Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) increased 3.52% to close at $4.71. Its volatility for the week is 8.43% while volatility for the month is 6.93%. ANTH’s EPS growth for past 5 years was 53.80%. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) monthly performance is 8.03%. Zacks restated their buy rating on shares of Anthera Pharmaceuticals (NASDAQ:ANTH) in a report issued on Friday. They currently have a $5.75 target price on the stock.
On Monday shares of UGI Corporation (NYSE:UGI) closed at $35.40. Company’s sales growth for last 5 years was 7.60% and EPS growth for next 5 years is recorded as 6.20%. UGI Corporation (NYSE:UGI) reported second-quarter net income attributable to company of $246.5 million, or $1.40 per share, compared to $214.4 million, or $1.22 per share, for the prior-year period. Adjusted net income attributable to company was $215.7 million, or $1.23 per share, for the fiscal quarter ended March 31, 2015.
On last trading day Freescale Semiconductor, Ltd. (NYSE:FSL) fell -0.71% to close at $40.63. Its volatility for the week is 3.31% while volatility for the month is 2.31%. FSL’s sales growth for past 5 years was 5.70% and its EPS growth for past 5 years was -23.30%. Freescale Semiconductor, Ltd. (NYSE:FSL) monthly performance is 0.92%. Freescale Semiconductor (NYSE:FSL) is scheduled to present at the J.P. Morgan Global Technology, Media and Telecom Conference. Dan Durn, senior vice president and CFO, and Mitch Haws, vice president, investor relations, will present for the company, on Monday, May 18, 2015.